Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Exp Rheumatol. 2016 Sep-Oct;34(5):848-856. Epub 2016 Jun 22.

Effects of treatment with etanercept versus methotrexate on sleep quality, fatigue and selected immune parameters in patients with active rheumatoid arthritis.

Author information

  • 1Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Germany.
  • 2Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin; and German Rheumatism Research Center (Deutsches Rheumaforschungszentrum, DRFZ), Berlin, Germany.
  • 3Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin; German Rheumatism Research Center (Deutsches Rheumaforschungszentrum, DRFZ); and Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Berlin, Germany.
  • 4Sleep Medicine Center, Charité-Universitätsmedizin Berlin, Germany.
  • 5Medical Director Global Innovative Pharma, Pfizer Pharma GmbH, Berlin, Germany.
  • 6pj statistics, Berlin, Germany.
  • 7Laboratory of Experimental Rheumatology and Neuroendocrino-Immunology, Department of Internal Medicine I, University Hospital Regensburg, Regensburg, Germany.

Abstract

OBJECTIVES:

To compare sleep quality, disease activity and patient-reported outcomes such as fatigue and immune parameters in patients with rheumatoid arthritis treated with etanercept (ETA) or methotrexate (MTX).

METHODS:

Of 36 patients (28-joint Disease Activity Score, DAS28CRP≥3.2) in this 16-week (w), open, prospective study, 19 (11 women) received MTX 12.5-17 mg/w, and 17 (14 women) received ETA 25 mg x 2/w, alone or in combination with MTX. Clinical (DAS28CRP, visual analogue scale), laboratory (C-reactive protein [CRP]), sleep (polysomnography), functional (Multidimensional Fatigue Inventory; Health Assessment Questionnaire-Disability Index (HAQ-DI); 36-item Short-Form Health Survey (SF-36), immunological (humoral/cellular) and neuroendocrine (hormonal) parameters were recorded at baseline (BL), w8 and w16.

RESULTS:

BL characteristics did not differ significantly between the ETA and MTX groups except disease duration: mean age (years): 48.6±8.8 vs. 49.4±16.6; mean disease duration (months): 19.6±46.3 vs. 81.2±79.2; and DAS28CRP: 4.4±0.9 vs. 4.4±1.7, respectively. DAS28CRP, SF-36, and HAQ-DI improved significantly in both groups from BL to w16 (p≤0.05). The DAS28CRP improvements at w16 (mean changes -1.8 in the ETA group, and -1.4 in MTX group), were not statistically significant from each other. The absolute values of sleep efficiency, total sleep time, and stage 2 sleep duration increased significantly in the ETA group, but no significant changes were reported in the MTX group.

CONCLUSIONS:

Both therapies improved disease activity, CRP, SF-36 and HAQ-DI, with faster, more pronounced changes in DAS28CRP in the ETA group, which alone had significantly improved sleep parameters.

PMID:
27385076
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Clinical and Experimental Rheumatology
    Loading ...
    Support Center